drug · antibody
ramucirumab
Phase 3updated 3mo agoby Eli Lilly and Co🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 18 investigational indications.
indications
indications
NSCLC
targets
Vascular endothelial growth factor receptor 2
all catalysts(0)
nothing on the calendar yet
Trials studying ramucirumab
- phase2Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- phase2A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- phase2Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- phase2CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- phase2Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
- phase3Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- phase2A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
- phase2A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that